Chimeric Therapeutics is trading at A$0.01, down 14.29%, after declining on September 22, 2026, with no clear company-specific catalyst identified. - The ASX announcement list showed no new Chimeric filing for September 21. - Coverage concerned a September 18 application to quote 14,814,814 new shares, updated September 22. - Broader market conditions were broadly flat, so the decline cannot be confidently attributed to global sentiment.